Literature DB >> 6115666

Comparison of four different beta-adrenoceptor blocking drugs on lymphocyte isoprenaline-stimulated cyclic AMP production.

D R Lima, S Kilfeather, A Hedges, P Turner.   

Abstract

1 The influence of acebutolol, atenolol, pindolol and timolol on human lymphocyte cyclic AMP (cAMP) and its stimulation by isoprenaline in vitro has been studied. 2 Acebutolol and atenolol (10(-8)-10(-6)M) had no significant influence on lymphocyte cAMP levels or on isoprenaline-stimulated increase in cAMP. 3 Pindolol and timolol significantly antagonised the effect of isoprenaline, and pA2 values were calculated to be 8.12 and 8.04 respectively. This suggests that beta 2-adrenoceptors are involved in this phenomenon. 4 Only pindolol produced a significant increase in lymphocyte cAMP, which is consistent with its partial agonist activity.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 6115666      PMCID： PMC1402205          DOI： 10.1111/j.1365-2125.1981.tb01170.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


  9 in total

Review 1.  The assessment of beta-adrenoceptor blocking drugs in man.

Authors:  D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1977-08       Impact factor: 4.335

Review 2.  The second Lilly Prize Lecture, University of Newcastle, July 1977. beta-Adrenergic receptor blockade in hypertension, past, present and future.

Authors:  B N Prichard
Journal:  Br J Clin Pharmacol       Date:  1978-05       Impact factor: 4.335

3.  Radioimmunoassay for cyclic nucleotides. I. Preparation of antibodies and iodinated cyclic nucleotides.

Authors:  A L Steiner; C W Parker; D M Kipnis
Journal:  J Biol Chem       Date:  1972-02-25       Impact factor: 5.157

4.  A potent beta-adrenoreceptor blocking drug: 4-(2-hydroxy-3-isopropylaminopropoxy)indole.

Authors:  G E Moore; S R O'Donnell
Journal:  J Pharm Pharmacol       Date:  1970-03       Impact factor: 3.765

5.  Comparison of a new beta adrenergic blocker (MK 950) and propranolol in man.

Authors:  M Ulrych; J Franciosa; J Conway
Journal:  Clin Pharmacol Ther       Date:  1972 Mar-Apr       Impact factor: 6.875

6.  Beta-adrenoceptors in human lung, bronchus and lymphocytes.

Authors:  C Davis; M E Conolly; J K Greenacre
Journal:  Br J Clin Pharmacol       Date:  1980-11       Impact factor: 4.335

7.  Timolol maleate, a new beta-adrenergic receptor blocking agent.

Authors:  R A Hall; R D Robson; N N Share
Journal:  Arch Int Pharmacodyn Ther       Date:  1975-02

8.  The beta-adrenoceptor of the human lymphocyte and human lung parenchyma.

Authors:  M E Conolly; J K Greenacre
Journal:  Br J Pharmacol       Date:  1977-01       Impact factor: 8.739

9.  The selective action of beta-adrenoceptor blocking drugs and the nature of beta1 and beta2 adrenoceptors.

Authors:  A J Coleman; A R Somerville
Journal:  Br J Pharmacol       Date:  1977-01       Impact factor: 8.739
  9 in total
  4 in total

1.  Effects of three beta-blockers with different pharmacodynamic properties on platelet aggregation and platelet and plasma cyclic AMP.

Authors:  K Winther; J Trap-Jensen
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

2.  Ethnic differences in human lymphocytic cyclic AMP production after isoprenaline stimulation and propranolol blockade.

Authors:  C P Venter; S Daya; P H Joubert; W J Strydom
Journal:  Br J Clin Pharmacol       Date:  1985-02       Impact factor: 4.335

Review 3.  Pindolol--a beta-adrenoceptor blocking drug with partial agonist activity: clinical pharmacological considerations.

Authors:  W H Aellig
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

4.  Influence of intravenous beta-adrenergic blockade with or without partial agonist activity upon plasma cyclic AMP and catecholamines in healthy subjects.

Authors:  C Gennari; G Pollavini; R Nami; G Francini; C Bianchini; P Verdecchia
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.